Explore Business Standard
Explore Business Standard
The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.
| Category | Q3 FY25-26 | Q3 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 3,900.62 | 3,387.55 | 15.15 | 13,321.74 | 11,813.10 | 12.77 |
| Expenses | 3,215.20 | 2,787.32 | 15.35 | 11,343.18 | 11,518.72 | -1.52 |
| Other Income | 44.47 | 31.13 | 42.85 | 113.72 | 1,237.32 | -90.81 |
| Operating Profit | 85.90 | 83.42 | 2.97 | 2,092.28 | 1,531.70 | 36.60 |
| Depreciation | 154.45 | 122.74 | 25.84 | 486.01 | 581.91 | -16.48 |
| Interest | 41.43 | 52.29 | -20.77 | 207.07 | 515.97 | -59.87 |
| Profit Before Tax | 534.00 | 456.32 | 17.02 | 1,399.21 | 433.82 | 222.53 |
| Tax | 130.77 | 108.29 | 20.76 | 382.34 | 1,115.55 | -65.73 |
| Net Profit | 587.55 | 347.96 | 68.86 | 1,047.14 | -1,433.52 | -173.05 |
| Category | Q3 FY25-26 | Q3 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 2,359.93 | 2,251.28 | 4.83 | 9,226.41 | 7,891.12 | 16.92 |
| Expenses | 2,041.30 | 1,757.35 | 16.16 | 7,161.40 | 6,649.46 | 7.70 |
| Other Income | 109.06 | 129.19 | -15.58 | 356.37 | 6,238.36 | -94.29 |
| Operating Profit | 1,765.66 | 1,835.99 | -3.83 | 2,421.38 | 7,480.02 | -67.63 |
| Depreciation | 59.18 | 55.16 | 7.29 | 218.63 | 202.16 | 8.15 |
| Interest | 21.98 | 8.46 | 159.81 | 48.73 | 277.11 | -82.41 |
| Profit Before Tax | 346.53 | 559.49 | -38.06 | 2,154.02 | 7,000.74 | -69.23 |
| Tax | 64.46 | 145.69 | -55.76 | 316.09 | 1,049.99 | -69.90 |
| Net Profit | 282.07 | 413.80 | -31.83 | 1,610.35 | 5,167.29 | -68.84 |
| Category | Q3 FY25-26 | Q2 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 3,900.62 | 6,046.87 | -35.49 |
| Expenses | 3,215.20 | 5,072.44 | -36.61 |
| Other Income | 44.47 | 200.63 | -77.83 |
| Operating Profit | 85.90 | 267.09 | -67.84 |
| Depreciation | 154.45 | 141.20 | 9.38 |
| Interest | 41.43 | 66.46 | -37.66 |
| Profit Before Tax | 534.00 | 967.40 | -44.80 |
| Tax | 130.77 | 356.97 | -63.37 |
| Net Profit | 587.55 | 1,995.47 | -70.56 |
| Category | Q3 FY25-26 | Q2 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 2,359.93 | 1,538.66 | 53.38 |
| Expenses | 2,041.30 | 2,648.45 | -22.92 |
| Other Income | 109.06 | 285.76 | -61.84 |
| Operating Profit | 1,765.66 | 285.93 | 517.51 |
| Depreciation | 59.18 | 58.93 | 0.42 |
| Interest | 21.98 | 23.40 | -6.07 |
| Profit Before Tax | 346.53 | -906.37 | -138.23 |
| Tax | 64.46 | -167.18 | -138.56 |
| Net Profit | 282.07 | -739.19 | -138.16 |
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Data not available.
| Company | 1 Day | 1 Week | 1 Month | 3 Months | 6 Month | 1 Year |
|---|---|---|---|---|---|---|
| Data Not Found | ||||||
Glenmark Pharmaceuticals Ltd on Monday said its arm Glenmark Specialty SA has received approval from China's National Medical Products Administration for the nasal spray RYALTRIS used to treat allergic rhinitis. The National Medical Products Administration (NMPA) of China has approved RYALTRIS Compound Nasal Spray (GSP 301 NS) for the treatment of allergic rhinitis (AR) in adults and children -- specifically for treatment of moderate to severe seasonal AR in adults and pediatric patients 6 years of age and older, and moderate to severe perennial AR in adults and pediatric patients 12 years of age and older, the company said in a statement. The approval granted with zero supplementation requests is an important milestone in Glenmark's respiratory pipeline and reflects continued progress in advancing innovative and differentiated therapies for patients with chronic conditions, it added. "The approval of RYALTRIS in China is a significant step in expanding our specialty respiratory ...
